Abeona Therapeutics
ABEO
98 hedge funds and large institutions have $138M invested in Abeona Therapeutics in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 13 reducing their positions, and 11 closing their positions.
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
127% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 11
13% more funds holding
Funds holding: 87 → 98 (+11)
12% more call options, than puts
Call options by funds: $582K | Put options by funds: $521K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.25% less ownership
Funds ownership: 2.61% → 2.36% (-0.25%)
40% less capital invested
Capital invested by funds: $230M → $138M (-$91.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$14.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.68M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.92M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.4M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.12M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.58M |
| 5 |
PA
Perceptive Advisors
New York
|
-$1.33M |
ABEO Hedge Fund Activity: Q2 2019 in Review
98 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2019, worth a combined $138M — down 40% from $230M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ABEO positions and 11 closed out — a net gain of 14 holders — while 33 added to existing stakes and 13 trimmed.
The largest buyer was Millennium Management, adding an estimated $14.6M. The largest seller was Fidelity Investments, cutting an estimated $19.8M.
- 98 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2019, up from 87 in Q1 2019.
- Funds reported $138M of Abeona Therapeutics stock for Q2 2019, down 40% quarter-over-quarter.
- 25 funds opened new Abeona Therapeutics positions in Q2 2019 and 11 closed out, a net change of +14 holders.
- The largest Abeona Therapeutics buyer in Q2 2019 was Millennium Management, an estimated $14.6M added.
- The largest Abeona Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $19.8M sold.
Based on aggregated 13F filings for Q2 2019.